Core Insights - The pharmaceutical company reported that the combination of giredestrant and everolimus significantly improved progression-free survival in patients with advanced breast cancer [1] Company Summary - The company is focused on developing treatments for advanced breast cancer, highlighting the efficacy of giredestrant in combination with everolimus [1] Industry Summary - The advancement in treatment options for advanced breast cancer is crucial, as it addresses a significant need in the oncology market [1]

Core Viewpoint - Genentech, a member of the Roche Group, announced positive results from the Phase III evERA study for giredestrant in combination with everolimus for treating specific breast cancer patients [1] Group 1: Study Results - The Phase III evERA study evaluated giredestrant combined with everolimus in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [1] - The study focused on patients who had previously been treated with a CDK 4/6 inhibitor and endocrine therapy [1]

evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The all-oral combination was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments; no new safety signals were observed evERA is the first positive head-to-head phase III trial investigating an all-oral selective oestrogen receptor deg ...